Kairos Pharma to acquire to two clinical-stage oncology assets from Celyn

Kairos Pharma (KAPA) announced the signing of a term sheet for a strategic asset acquisition with Celyn Therapeutics. Under the proposed terms of the agreement, Kairos Pharma will acquire worldwide rights to two clinical-stage oncology assets targeting non-small cell lung cancer: CL-273, a pre-IND, reversible, wild-type-sparing pan-EGFR inhibitor, and CL-741, a Phase 1-ready, orally available type IIb c-MET kinase inhibitor. John Yu, Kairos Pharma CEO, commented: “We anticipate this acquisition will significantly expand our oncology pipeline with late-preclinical and Phase 1-ready assets in a multi-billion dollar market with substantial unmet medical needs. With this acquisition, if completed, we will strengthen our armamentarium to reverse oncology drug resistance – by implementing therapeutics that specifically target resistance mutations that arise from targeting the EGFR receptor. Importantly, our established clinical consortia on the West Coast, anchored at Cedars-Sinai Medical Center in Los Angeles, provides us with the clinical infrastructure and expertise to rapidly initiate and execute Phase 1 and Phase 2 studies for both compounds.”